Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Cooper

Showing results (151-160 of 324) with videos related to

Pageof 33
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 16, 2005
A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infectionPeter G Cardiello, Elly Hassink, Jintanat Ananworanich, et al.
AIDS Research and Human Retroviruses|June 9, 2009
Evolution of CD4+ T cell count in HIV-1-infected adults receiving antiretroviral therapy with sustained long-term virological suppressionHelen Byakwaga, John M Murray, Kathy Petoumenos, et al.
AIDS (London, England)|April 11, 2006
Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men--a randomized, placebo-controlled studyPatrick W G Mallon, John Miller, Jason C Kovacic, et al.
AIDS (London, England)|December 5, 2013
Interleukin-6 and D-dimer levels at seroconversion as predictors of HIV-1 disease progressionElizabeth Hamlyn, Sarah Fidler, Wolfgang Stöhr, et al.
AIDS (London, England)|December 20, 2007
Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phaseJohn M Murray, Sean Emery, Anthony D Kelleher, et al.
AIDS (London, England)|April 21, 2004
Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension StudyAllison Martin, Don E Smith, Andrew Carr, et al.
AIDS (London, England)|April 21, 2011
Economic evaluation of monitoring virologic responses to antiretroviral therapy in HIV-infected children in resource-limited settingsKaren Schneider, Thanyawee Puthanakit, Stephen Kerr, et al.
AIDS (London, England)|May 23, 2012
Reclassification of risk of death with the knowledge of D-dimer in a cohort of treated HIV-infected individualsAmit C Achhra, Janaki Amin, Caroline Sabin, et al.
Plos One|February 28, 2015
Differences in the direction of change of cerebral function parameters are evident over three years in HIV-infected individuals electively commencing initial cARTAlan Winston, Rebekah Puls, Stephen J Kerr, et al.
Journal of Virology|July 29, 2004
Frequent transmission of cytotoxic-T-lymphocyte escape mutants of human immunodeficiency virus type 1 in the highly HLA-A24-positive Japanese populationTae Furutsuki, Noriaki Hosoya, Ai Kawana-Tachikawa, et al.
Pageof 33

Showing results (151-160 of 324) with videos related to

Sort By:
Pageof 33
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 16, 2005
A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infectionPeter G Cardiello, Elly Hassink, Jintanat Ananworanich, et al.
AIDS Research and Human Retroviruses|June 9, 2009
Evolution of CD4+ T cell count in HIV-1-infected adults receiving antiretroviral therapy with sustained long-term virological suppressionHelen Byakwaga, John M Murray, Kathy Petoumenos, et al.
AIDS (London, England)|April 11, 2006
Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men--a randomized, placebo-controlled studyPatrick W G Mallon, John Miller, Jason C Kovacic, et al.
AIDS (London, England)|December 5, 2013
Interleukin-6 and D-dimer levels at seroconversion as predictors of HIV-1 disease progressionElizabeth Hamlyn, Sarah Fidler, Wolfgang Stöhr, et al.
AIDS (London, England)|December 20, 2007
Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phaseJohn M Murray, Sean Emery, Anthony D Kelleher, et al.
AIDS (London, England)|April 21, 2004
Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension StudyAllison Martin, Don E Smith, Andrew Carr, et al.
AIDS (London, England)|April 21, 2011
Economic evaluation of monitoring virologic responses to antiretroviral therapy in HIV-infected children in resource-limited settingsKaren Schneider, Thanyawee Puthanakit, Stephen Kerr, et al.
AIDS (London, England)|May 23, 2012
Reclassification of risk of death with the knowledge of D-dimer in a cohort of treated HIV-infected individualsAmit C Achhra, Janaki Amin, Caroline Sabin, et al.
Plos One|February 28, 2015
Differences in the direction of change of cerebral function parameters are evident over three years in HIV-infected individuals electively commencing initial cARTAlan Winston, Rebekah Puls, Stephen J Kerr, et al.
Journal of Virology|July 29, 2004
Frequent transmission of cytotoxic-T-lymphocyte escape mutants of human immunodeficiency virus type 1 in the highly HLA-A24-positive Japanese populationTae Furutsuki, Noriaki Hosoya, Ai Kawana-Tachikawa, et al.
Pageof 33